🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Clinical Trials in Turkey / NCT07633730
Recruiting Not applicable

Efficacy of the Erector Spinae Plane Block for Persistent Back Pain in Patients With Ankylosing Spondylitis

NCT07633730 · tracked via the Priya Life Science Turkey tracker
Phase
Not applicable
Started
2026-06-02
Last updated
2026-06-08

Condition(s) studied

Ankylosing Spondylitis (AS)Back PainESPBRegional Anesthesia

Investigational drug(s) / intervention(s)

Erector spinae plane block(ESBP)

Erector spinae plane block(ESBP): The procedure will be performed in the prone position under sterile conditions and ultrasound guidance. Using a 22-gauge needle at the T5-T7 vertebral levels, the fascial plane between the deep fascia of the erector spinae muscle group and the transverse process of the vertebra will be accessed. A combination consisting of 5 cc of 0.5% bupivacaine, 4 cc of 0.9% normal saline, and 1 cc dexamethasone (8 mg/2 mL) will then be injected into the targeted plane. The procedure will be performed by experienced algology specialists with more than 15 years of experience in ultrasound-guided interventional procedures and will be administered in two sessions within one week.

Study summary

Despite adequate control of disease activity with standard medical therapies, there remains an ongoing need for complementary and interventional approaches for the management of persistent back pain in patients with ankylosing spondylitis. Although the erector spinae plane block has been described in the literature as a safe and effective analgesic intervention for chronic back pain in various patient populations, to the best of our knowledge, no clinical study has specifically evaluated its use for persistent back pain in patients with ankylosing spondylitis receiving medical treatment. Therefore, the present study aims to evaluate the effects of erector spinae plane block on pain severity and clinical outcomes in patients with ankylosing spondylitis whose disease activity is controlled under treatment but who continue to experience persistent back pain.

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: * Age between 18 and 65 years * Diagnosis of ankylosing spondylitis according to the Modified New York Criteria * Patients receiving ongoing treatment with controlled disease activity but persistent back pain * Willingness to participate in the study Exclusion Criteria: * Body mass index (BMI) greater than 35 kg/m² * History of thoracic surgery * Intellectual disability or mental retardation * Presence of major psychiatric comorbidity * Congenital spinal anomaly * Pregnancy * History of bleeding diathesis * Presence of active local and/or systemic infection * Known allergy to the medications to be injected * Hemodynamic instability * Active phase of the disease (elevated acute phase reactants, active arthritis findings, etc.)

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Marmara University Faculty of Medicine Pendik Training and Research Hospital Istanbul Pendik Recruiting

More Marmara University trials in Turkey

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07633730 on ClinicalTrials.gov ↗ ← All trials in Turkey